vs

Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.

FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $11.9M, roughly 1.2× ASCENT INDUSTRIES CO.). ASCENT INDUSTRIES CO. runs the higher net margin — -8.8% vs -34.7%, a 26.0% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 13.3%). Over the past eight quarters, FENNEC PHARMACEUTICALS INC.'s revenue compounded faster (-26.3% CAGR vs -34.9%).

Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.

Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.

ACNT vs FENC — Head-to-Head

Bigger by revenue
FENC
FENC
1.2× larger
FENC
$13.8M
$11.9M
ACNT
Growing faster (revenue YoY)
FENC
FENC
+60.5% gap
FENC
73.8%
13.3%
ACNT
Higher net margin
ACNT
ACNT
26.0% more per $
ACNT
-8.8%
-34.7%
FENC
Faster 2-yr revenue CAGR
FENC
FENC
Annualised
FENC
-26.3%
-34.9%
ACNT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACNT
ACNT
FENC
FENC
Revenue
$11.9M
$13.8M
Net Profit
$-1.0M
$-4.8M
Gross Margin
14.6%
Operating Margin
-21.0%
-18.5%
Net Margin
-8.8%
-34.7%
Revenue YoY
13.3%
73.8%
Net Profit YoY
-1.2%
-141.1%
EPS (diluted)
$-0.11
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACNT
ACNT
FENC
FENC
Q4 25
$11.9M
$13.8M
Q3 25
$19.7M
$12.5M
Q2 25
$18.7M
$9.7M
Q1 25
$24.7M
$8.8M
Q4 24
$10.5M
$7.9M
Q3 24
$20.9M
$7.0M
Q2 24
$21.5M
$7.3M
Q1 24
$28.0M
$25.4M
Net Profit
ACNT
ACNT
FENC
FENC
Q4 25
$-1.0M
$-4.8M
Q3 25
$-2.1M
$-638.0K
Q2 25
$6.3M
$-3.2M
Q1 25
$-2.3M
$-1.2M
Q4 24
$-1.0M
$-2.0M
Q3 24
$-6.2M
$-5.7M
Q2 24
$-926.0K
$-5.6M
Q1 24
$-5.5M
$12.8M
Gross Margin
ACNT
ACNT
FENC
FENC
Q4 25
14.6%
Q3 25
29.7%
Q2 25
26.1%
Q1 25
19.3%
Q4 24
24.3%
Q3 24
14.4%
Q2 24
13.1%
Q1 24
8.3%
Operating Margin
ACNT
ACNT
FENC
FENC
Q4 25
-21.0%
-18.5%
Q3 25
-4.1%
-1.5%
Q2 25
-14.4%
-28.3%
Q1 25
-4.2%
-9.2%
Q4 24
-25.4%
-11.8%
Q3 24
-9.4%
-74.6%
Q2 24
-8.6%
-69.4%
Q1 24
-15.5%
54.2%
Net Margin
ACNT
ACNT
FENC
FENC
Q4 25
-8.8%
-34.7%
Q3 25
-10.6%
-5.1%
Q2 25
33.7%
-32.7%
Q1 25
-9.3%
-13.3%
Q4 24
-9.8%
-25.0%
Q3 24
-29.5%
-82.2%
Q2 24
-4.3%
-76.5%
Q1 24
-19.7%
50.6%
EPS (diluted)
ACNT
ACNT
FENC
FENC
Q4 25
$-0.11
$-0.17
Q3 25
$-0.22
$-0.02
Q2 25
$0.65
$-0.11
Q1 25
$-0.23
$-0.04
Q4 24
$-0.11
$-0.02
Q3 24
$-0.61
$-0.21
Q2 24
$-0.09
$-0.20
Q1 24
$-0.54
$0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACNT
ACNT
FENC
FENC
Cash + ST InvestmentsLiquidity on hand
$57.6M
$36.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$87.0M
$35.5M
Total Assets
$111.9M
$70.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACNT
ACNT
FENC
FENC
Q4 25
$57.6M
$36.8M
Q3 25
$58.0M
$21.9M
Q2 25
$60.5M
$18.7M
Q1 25
$14.3M
$22.7M
Q4 24
$16.1M
$26.6M
Q3 24
$8.5M
$40.3M
Q2 24
$3.6M
$43.1M
Q1 24
$1.3M
$51.2M
Total Debt
ACNT
ACNT
FENC
FENC
Q4 25
Q3 25
$19.4M
Q2 25
$19.4M
Q1 25
$19.4M
Q4 24
$0
$19.3M
Q3 24
$32.1M
Q2 24
$31.8M
Q1 24
$31.3M
Stockholders' Equity
ACNT
ACNT
FENC
FENC
Q4 25
$87.0M
$35.5M
Q3 25
$87.1M
$-4.5M
Q2 25
$89.7M
$-7.5M
Q1 25
$91.2M
$-5.9M
Q4 24
$93.5M
$-5.9M
Q3 24
$94.7M
$-5.2M
Q2 24
$101.0M
$-1.4M
Q1 24
$102.0M
$3.0M
Total Assets
ACNT
ACNT
FENC
FENC
Q4 25
$111.9M
$70.6M
Q3 25
$119.9M
$49.3M
Q2 25
$122.6M
$44.9M
Q1 25
$152.5M
$46.4M
Q4 24
$147.3M
$44.9M
Q3 24
$148.6M
$58.9M
Q2 24
$158.2M
$63.2M
Q1 24
$161.0M
$69.2M
Debt / Equity
ACNT
ACNT
FENC
FENC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24
10.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACNT
ACNT
FENC
FENC
Operating Cash FlowLast quarter
$266.0K
$-6.0M
Free Cash FlowOCF − Capex
$-196.0K
FCF MarginFCF / Revenue
-1.7%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-2.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACNT
ACNT
FENC
FENC
Q4 25
$266.0K
$-6.0M
Q3 25
$1.3M
$1.5M
Q2 25
$-1.4M
$-3.7M
Q1 25
$-700.0K
$-4.3M
Q4 24
$8.8M
$-1.5M
Q3 24
$3.4M
$-2.2M
Q2 24
$2.2M
$-8.4M
Q1 24
$263.0K
$39.0M
Free Cash Flow
ACNT
ACNT
FENC
FENC
Q4 25
$-196.0K
Q3 25
$695.0K
Q2 25
$-1.5M
Q1 25
$-1.0M
Q4 24
$8.4M
Q3 24
$3.1M
Q2 24
$1.9M
Q1 24
$25.0K
FCF Margin
ACNT
ACNT
FENC
FENC
Q4 25
-1.7%
Q3 25
3.5%
Q2 25
-8.3%
Q1 25
-4.1%
Q4 24
80.6%
Q3 24
15.1%
Q2 24
9.1%
Q1 24
0.1%
Capex Intensity
ACNT
ACNT
FENC
FENC
Q4 25
3.9%
Q3 25
3.1%
Q2 25
0.8%
Q1 25
1.3%
Q4 24
3.7%
Q3 24
1.3%
Q2 24
1.0%
Q1 24
0.9%
Cash Conversion
ACNT
ACNT
FENC
FENC
Q4 25
Q3 25
Q2 25
-0.22×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
3.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACNT
ACNT

Other$6.1M52%
Transferred At Point In Time$5.7M48%

FENC
FENC

Segment breakdown not available.

Related Comparisons